Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Hughes, Timothy P
  • Cervantes, Francisco
  • Spector, Nelson
  • Leber, Brian
  • Branford, Susan
  • Glynos, Tara A
  • Acharya, Sandip
  • Dalal, Darshan
  • Lipton, Jeffrey H

publication date

  • December 3, 2015

published in